About
Therapies for Apoptosis-driven Diseases
Tamarix Pharma is an early-stage biotech company focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.
The company's lead assets are VBIT-4 and VBIT-12, small molecules targeting VDAC1 oligomerization. They were deliberately designed to target a key mitochondrial process known as VDAC1 oligomerization. Their unique mechanism of action represents a highly differentiated approach to potentially treating a variety of acute and chronic conditions resulting from apoptotic cell death.
Identity
| Name | Tamarix Pharma |
|---|---|
| Slug | tamarix-pharma |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Luasa4JDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, May 2023 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Professor Rakakh Street 1, Jerusalem, Israel |
Web & social
| https://www.linkedin.com/company/tamarix-pharma |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsneurologybiochemical-compoundscell-therapytherapeuticsbiotechnology
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}